The cost-cutting plan Pear Therapeutics announced in July has not done enough to change the company’s financial outlook, suggesting the company’s strategy to sell digital therapeutics to state health agencies is not nearly as effective as the company’s investors had hoped.
The restructuring plan that Pear announced last summer included two rounds of layoffs, cutting about 20% of the company’s staff. At the time, the company hoped these job cuts could...